REPL — AI Stock Analysis & Recommendation

TradeFlare's AI research teams rate REPL a HOLD with a conviction of 25/100. The current price is $12.87.

• Entry: $12.87

N/A. Catalysts to watch: Successful commercialization and market adoption of TUDRIQEV™; Positive clinical trial results for RP1 and other pipeline candidates; Favorable regulatory outcomes for future drug approvals. Key risks: High cash burn rate and potential for future dilution due to pre-revenue status; Clinical trial failures or setbacks for key pipeline assets; Intense competition in the oncology space.

FlareScore breakdown — Technical: 40 · Fundamental: 60 · Sentiment: 55 · Risk: 10

Last updated September 18, 2026 · AI-generated analysis for informational purposes, not financial advice.